Fig 1.
Map showing the location of 23 inclusion study sites in N’Djamena, Chad, including 5 out of 10 districts randomly selected in which neighborhoods were further chosen for awareness of the study [1st district: Farcha, Amsinéné, Karkandjeri; 3rd district: Gardolé, Ardep Djoumal, Kabalaye, Sabangali; 6th district: Moursal, Paris-Congo; 7th district: Ambata, Amtoukoui, Atrone, Boutalbagara, Chagoua, Dembé, Gassi, Habena, Kilwiti; 9th district: Digagali, Gardolé, Ngueli, Tourka, Wali].
In each inclusion site, peer educators contacted adult women in community-churches or women associations during a one-month period and proposed them to be included in the study after an oral explanation and collective awareness sessions on the objectives of the survey, mainly focused on information on cervical cancer.
Table 1.
Baseline characteristics of 253 adult women living in N’Djamena, in Chad.
Fig 2.
Distribution of HPV genotypes according to their inclusion in the 9-valent Gardasil-9 vaccine.
Number of low-risk (LR) and high-risk (HR) HPV genotypes in 57 cervical samples positive for HPV DNA by molecular biology according to their possible prevention by 9-valent HPV vaccine among adult women (n = 253) living in N’Djamena, Chad. Nota bene. The 9-valent Gardasil-9 vaccine (Merck & Co. Inc., New Jersey, USA) is effective against HPV genotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58.
Fig 3.
Distribution of HPV types in 57 adult women.
A. According to age groups; B. According to age at first sexual intercourse.
Table 2.
Logistic regression analyses for cervical HPV-associated risk factors in 253 adult women living in N’Djamena, Chad.